Going After Gravity: How A High-Risk Project Got Funded

CAMBRIDGE, MASS.—If Rainer Weiss doesn't reach his goal of staring God in the eye—or at least gazing back to the first moment of creation—it won't be for lack of trying. Over the past 16 years, the Massachusetts Institute of Technology physicist has appeared before a host of committees, flitted between coasts on red-eye flights to meet with collaborators, and even endured what some call a scientific version of a shotgun wedding with rival physicists at Caltech. For the pipe-smo

Written byRobert Buderi
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

For the pipe-smoking Weiss, the trials and tribulations are proving worth it. Two months ago, he and the Caltech physicists, who are now overseeing the direction of the project, received a multimilliondollar nod to forge ahead with their dream of detecting gravity waves— an unverified, extremely weak form of radiation predicted by Einstein's general theory of relativity.

Indeed, at a time when funds seem to be tightening up, the National Science Foundation renewed a commitment to the project and upped the money the plan is approved to receive—to $10.6 million over the next 30 months. And NSF officials are optimistic that the 1990 budget will allocate another $100 million to build the first full-scale gravity wave observatories.

An example of the kind of "big science" project that NSF approves only a few times each decade, the grandiose scheme calls for a huge L-shaped detector on each coast of the United ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies